Coherus BioSciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2020 Annual Meeting of Stockholders held virtually on May 22, 2020. The Company, Coherus BioSciences, Inc., is incorporated in Delaware and trades on The Nasdaq Global Market under the symbol CHRS. As of the record date of March 31, 2020, there were 70,882,994 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Three proposals were voted upon by stockholders, with 62,847,211 shares voted in total:
- Proposal 1 (Election of Directors): Stockholders elected Class III director nominees. Dennis M. Lanfear and Mats Wahlström received majority support. James I. Healy, M.D., Ph.D., received 28,003,660 votes for, but 29,922,883 votes were withheld, resulting in a plurality win despite significant opposition.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020, with 62,651,042 votes in favor.
- Proposal 3 (Say on Pay): Stockholders approved the non-binding advisory resolution on executive compensation with 47,962,229 votes in favor, 9,652,279 against, and 312,035 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific reasons for the high number of withheld votes (29.9 million) against director nominee James I. Healy, M.D., Ph.D.
- Confirm the total number of broker non-votes (4,920,668) and their impact on the quorum and voting thresholds.
- Review the Definitive Proxy Statement on Schedule 14A filed on April 6, 2020, for detailed background on the director nominees and executive compensation.